Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. RaySearch Laboratories AB (publ)
  6. News
  7. Summary
    RAY B   SE0000135485

RAYSEARCH LABORATORIES AB (PUBL)

(RAY B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

RaySearch Laboratories : Cutting-edge cancer treatment comes to Belgium with the installation of RayCare and RayStation at Particle Therapy Interuniversity Centre Leuven

09/16/2020 | 02:46am EDT

Advanced treatment planning system (TPS) RayStation®* and next-generation oncology information system (OIS) RayCare®* are now in operation at the brand new Particle Therapy Interuniversity Centre Leuven (PARTICLE). The center is the first proton therapy clinic in the world with the combination of RayCare and IBA's single-room proton therapy device Proteus®ONE.

[image]

Part of an interuniversity project of University Hospitals Leuven (together with KU Leuven and Cliniques universitaires Saint-Luc, UCLouvain and supported by UZ Gent, CHU UCL Namur, UZ Brussel and UZA), PARTICLE has been created to offer clinical care, in addition to education, training and research and development.

The collaborative center has partnered with leading academic partners and research institutes, as well as with industrial partners such as RaySearch, supplier of RayCare and RayStation, and IBA, the supplier of the proton therapy device ProteusONE.

RayCare is designed to enable clinicians to fluidly coordinate tasks and ensure optimal use of resources. PARTICLE is the first proton therapy center in the world to install RayCare to support comprehensive cancer care and treatment delivery in combination with ProteusONE, a compact proton beam therapy device featuring the latest generation pencil beam scanning and isocenter volumetric imaging capabilities.

Together, the advanced software from RaySearch and cutting-edge equipment from IBA will position PARTICLE at the forefront of innovative cancer treatment in Belgium. The combination of the technologies will help patients in the country gain critical access to proton therapy, which is the optimal option for cancer patients where treatment options are limited, or where conventional radiotherapy presents an unacceptable risk to the patient - as is often the case with children. In addition, having a dedicated proton therapy located about 25 kilometers (16 miles) east of the capital Brussels will help patients avoid the need to travel abroad to access proton therapy treatment.

Prof. Ir. Tom Depuydt, Head of Medical Physics, UZ Leuven, says: "Going live with the proton therapy facility is an exciting time for us at UZ Leuven. When it came to choosing the software, it was really important that the OIS was streamlining the proton therapy workflow throughout the department. We wanted to make sure the OIS and a really innovative TPS are well integrated with each other and with the treatment machine. The choice for RayCare and RayStation was in line with this vision. The integration will make it possible to move forward into adaptive treatment, one of the new ways of radiation therapy."

Johan Löf, founder and CEO, RaySearch, says: "The inauguration of the collaborative PARTICLE center represents an important milestone for proton therapy in Europe. The work carried out at the center will be propelled by an exciting combination of innovative hardware and a powerful software environment with RayStation and RayCare."

For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com

Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59
peter.thysell@raysearchlabs.com

About RaySearch
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.

About RayStation
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.

About RayCare
RayCare is designed to support the complex logistical challenges of modern oncology clinics. It represents the future of oncology information system technology, supporting the vision of one oncology workflow. Many cancer patients receive a combination of treatment types, and RayCare is designed to reflect that. It will efficiently coordinate activities in radiation therapy, chemotherapy and surgery and will offer advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. RayCare is being developed with tomorrow's requirements for advanced analytics and decision support in mind.

* Subject to regulatory clearance in some markets.

More information about RaySearch is available at www.raysearchlabs.com

https://news.cision.com/raysearch-laboratories/r/cutting-edge-cancer-treatment-comes-to-belgium-with-the-installation-of-raycare-and-raystation-at-pa,c3194773

https://mb.cision.com/Main/1102/3194773/1306774.pdf

https://news.cision.com/raysearch-laboratories/i/pr-leuven-20-09-15,c2825139

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about RAYSEARCH LABORATORIES AB (PUBL)
07:56aRAYSEARCH LABORATORIES  : Signs extensive agreements with a clinic in switzerlan..
AQ
05/27RAYSEARCH LABORATORIES  : RayCare 5A brings new features for radiation therapy m..
AQ
05/26RAYSEARCH LABORATORIES  : Bulletin from the Annual General Meeting 2021
AQ
05/26RAYSEARCH LABORATORIES  : Annual report 2020
PU
05/26RAYSEARCH LABORATORIES  : RayStation latest release, ­­­­­­­­­­­­­­­­­­­­­­­­­­­..
PU
05/26RAYSEARCH LABORATORIES  : RayStation latest release, ­­­­­­­­­­­­­­­­­­­­­­­­­­­..
AQ
05/05RAYSEARCH LABORATORIES  : INTERIM REPORT JANUARY 1 – MARCH 31, 2021
PU
05/05RAYSEARCH LABORATORIES  : Interim report january 1 - march 31, 2021
AQ
05/04RAYSEARCH LABORATORIES  : Establishes local subsidiary for the australian and ne..
AQ
05/03RAYSEARCH LABORATORIES  : Expands its partnership with canon medical systems usa
AQ
More news
Financials
Sales 2021 883 M 104 M 104 M
Net income 2021 88,1 M 10,3 M 10,3 M
Net cash 2021 33,7 M 3,95 M 3,95 M
P/E ratio 2021 35,9x
Yield 2021 0,54%
Capitalization 3 085 M 361 M 362 M
EV / Sales 2021 3,45x
EV / Sales 2022 3,23x
Nbr of Employees 413
Free-Float 70,0%
Chart RAYSEARCH LABORATORIES AB (PUBL)
Duration : Period :
RaySearch Laboratories AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RAYSEARCH LABORATORIES AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 105,00 SEK
Last Close Price 92,20 SEK
Spread / Highest target 13,9%
Spread / Average Target 13,9%
Spread / Lowest Target 13,9%
EPS Revisions
Managers and Directors
NameTitle
Johan Löf President, Chief Executive Officer & Director
Peter Thysell Chief Financial Officer
Lars Micael Wollung Chairman
Kjell Eriksson Chief Research Officer
Carl Filip Bergendal Director
Sector and Competitors